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The rates of metabolic diseases, such as type 2 diabetes mellitus (T2DM), obesity,
and cardiovascular disease (CVD), markedly increase with age. In recent years,
studies have reported an association between metabolic changes and various
pathophysiological mechanisms in the central nervous system (CNS) in patients with
metabolic diseases. Oxidative stress and hyperglycemia in metabolic diseases lead to
adverse neurophysiological phenomena, including neuronal loss, synaptic dysfunction,
and improper insulin signaling, resulting in Parkinson’s disease (PD). In addition, several
lines of evidence suggest that alterations of CNS environments by metabolic changes
influence the dopamine neuronal loss, eventually affecting the pathogenesis of PD. Thus,
we reviewed recent findings relating to degeneration of dopaminergic neurons during
metabolic diseases. We highlight the fact that using a metabolic approach to manipulate
degeneration of dopaminergic neurons can serve as a therapeutic strategy to attenuate
pathology of PD.
Keywords: dopaminergic neurons, metabolic diseases, aging, neurodegenerative diseases, Parkinson’s
disease (PD)
INTRODUCTION
Changing lifestyles means that many older people suffer from metabolic syndromes, including
type 2 diabetes (T2DM), obesity, and cardiovascular disease (CVD; Luchsinger, 2010). Aging
is accompanied by a variety of physiological changes, such as mitochondrial dysfunction,
inflammation and a decline in insulin sensitivity (Dillin et al., 2002; Lee et al., 2003; Short
et al., 2005; Riera and Dillin, 2015), which finally lead to age-related diseases. According
to a recent survey, the prevalence of metabolic diseases increases by approximately 46.7%
among people older than 60 years compared to younger individuals (Sepúlveda and Murray,
2014). Furthermore, this prevalence increases by over 50% in people aged over 65 years
(Aguilar et al., 2015). Consequently, as the global population ages there will be a higher
prevalence of CVD, T2DM and obesity (Kalyani et al., 2014; Sepúlveda and Murray, 2014;
Hinnouho et al., 2015). Moreover, several studies have found that metabolic diseases are
significantly linked to neurodegenerative diseases such as Alzheimer’s disease (AD) and
Parkinson’s disease (PD; Anthony et al., 2006; Tezapsidis et al., 2009; Ahtiluoto et al.,
2010; Lara et al., 2013; Ninomiya, 2014). Patients with neurodegenerative diseases like
PD commonly suffer motor disturbance due to the degeneration or loss of dopaminergic
neurons (Michel et al., 2013; Kalia and Lang, 2015). In fact, one clinical research study
demonstrated that dopaminergic neuron activity strongly influences metabolic alterations in
humans (Brunerova et al., 2013). Thus, the loss of dopaminergic neurons and degeneration
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should be an area of research focus to identify a therapeutic
solution for metabolic change-induced PD. Here, we review
recent studies and provide new insight on the link between
metabolic diseases and the degeneration of dopaminergic
neurons, which consequently leads to PD.
THE ASSOCIATION BETWEEN METABOLIC
DISEASES AND PD
Among metabolic disorders, T2DM is associated with
neurodegenerative diseases, including diabetic neuropathy
and Alzheimer’s disease (Wild et al., 2004; Boulton et al.,
2005). In addition, recent studies reported a positive correlation
between diabetes and dementia risk (Cheng et al., 2012;
Gudala et al., 2013; Vagelatos and Eslick, 2013). According
to many epidemiological studies, the impairment of insulin
action in people with T2DM, could lead to brain dysfunction
(Boulton et al., 2005; Corti et al., 2011), such as cognitive
decline, compared to people not suffering from the disorder
(Lu and Hu, 2012). In particular, insulin resistance is thought
to promote chronic hyperglycemia (Ahtiluoto et al., 2010),
and leads to cognitive impairment and vascular dementia
by promoting the secretion of proinflammatory cytokines
(Ninomiya, 2014). Decreased insulin receptors in the PD brain
is related to neuronal loss in the substantia nigra (Moroo
et al., 1994). In fact, one clinical study suggested that diabetes
results in Parkinsonian signs such as postural reflex and gait
impairment (Arvanitakis et al., 2007). Furthermore, obesity is
considered the main cause of hypothalamic inflammation
(Tang et al., 2015). Excessive fat accumulation induces
inflammatory responses by promoting proinflammatory
cytokine production in the central nervous system (CNS;
Velloso et al., 2015). There is a strong relationship between high
levels of adipokines, generated by adipose tissues (Buchman
et al., 2005), and cognitive decline, and the former can be
used as a predictor of the latter (Zeki Al Hazzouri et al.,
2013). Some studies indicated a remarkable effect of leptin,
as an adipokine, on memory loss in obese animal models
(Bigalke et al., 2011; Theodoropoulou et al., 2012). Another
study demonstrated that leptin improves cognitive function
in mice that showed motor dysfunction and memory decline
(Farr et al., 2006). Furthermore, clinical studies report that
patients with metabolic disorder also show decreased cognitive
function (Vieira et al., 2011; Levin et al., 2014). Studies on
PD show significantly decreased heart function in patients
(Rodríguez et al., 1996; Kallio et al., 2000). The association
between cardiovascular autonomic dysfunction and PD has
been further highlighted by recent evidence (Cilia et al., 2015).
Also, high blood pressure considered an important risk factor
in CVD increases the prevalence of dementia (Qiu et al.,
2005). Many evidences indicate that hypertension and blood
pressure are strongly associated with neurotoxicity in the brain
(Langbaum et al., 2012; Toledo et al., 2012; Rodrigue et al.,
2013). Taken together, metabolic diseases including T2DM,
obesity, and CVD are linked to the onset and development
of PD. Considering connected consequences between these
disorders, we suggest that investigation for common issues




Dopamine is primarily regarded as a neurotransmitter that
controls the brain reward system (Blum et al., 2000). Midbrain
dopaminergic neurons in brain areas, such as the substantia
nigra pars compacta, regulate movement activation and cognitive
functions by binding dopamine D1 and D2 receptors (Palmiter,
2007, 2008; Kravitz et al., 2010; Tritsch and Sabatini, 2012;
Calabresi et al., 2014). In vivo pharmacological studies have
suggested that the blockade of dopamine receptors in the
dorsolateral prefrontal cortex and dorsal striatum, reduces
cognitive functions (Landau et al., 2009; Cools, 2011; Li
and Mei, 1994; Sawaguchi and Goldman-Rakic, 1994). Loss
of dopaminergic neurons triggers a deregulation of motor
symptoms such as rigidity and postural instability (Rodriguez-
Oroz et al., 2009; Masoud et al., 2015). PD is characterized by
the progressive loss of dopaminergic neurons of the substantia
nigra pars compacta that project to the striatum (Michel et al.,
2013; Kalia and Lang, 2015). Imaging studies in PD patients
have reported a positive correlation between cognitive deficits,
and the reduction of dopamine levels in the frontostriatal circuit
(Brück et al., 2001, 2005; Sawamoto et al., 2008; Jokinen et al.,
2009). Postmortem studies in PD patients have shown the loss
of cholinergic (Zweig et al., 1989), and dopaminergic neurons
(Karachi et al., 2010) which are crucial in the progression
of PD. Moreover, one study found that cognitive decline in
PD is strongly associated with the disruption of dopamine
signaling in the prefrontal cortex (Narayanan et al., 2013).
The pathology of PD is strongly linked to the death of
dopaminergic neurons and the presence of Lewy bodies (Chase
et al., 1998). Another study also reported a relationship between
dopamine neuron degeneration and cognitive impairments
(Bromberg-Martin et al., 2010). The intracellular mechanisms
of dopaminergic neurons, and the environmental conditions
around them, contribute to the progress of familial and sporadic
PD forms (Dauer and Przedborski, 2003; Rodriguez et al.,
2014; Ryan et al., 2015). The cellular mechanisms related to
dopaminergic neuron degeneration are associated with increased
sensitivity to mitochondrial dysfunction (Jeon et al., 1995;
Lotharius et al., 1999; Kann and Kovács, 2007) and changes
in protein degradation (Mosharov et al., 2009; Yacoubian
and Standaert, 2009; Dehay et al., 2015). These researches
indicated that the change of mitochondria energy metabolism
caused by metabolic changes influences the expression of
PD related proteins such as LRRK2, α-Syn, PINK-1, UCH-
L1, DJ-1. Recent studies found a number of causes for
dopaminergic neuron degeneration such as oxidative stress
(Segura-Aguilar et al., 2014), aging (Ba and Martin, 2015) and
neuroinflammation (Ryan et al., 2015). Based on these studies,
decreased dopamine transporters in dopaminergic neuron could
be used as the indicator to diagnose PD, in that the level
of dopamine decisively affects the pathology progress of PD.
The damage to dopaminergic neurons is mediated by the
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apoptosis signal, p53, which was found using an in vitro
PD model (Li et al., 2016). Based on previous evidence, the
degeneration of dopaminergic neurons is an important issue
in the progression of PD, and its mechanisms should be




Insulin Resistance and Dopaminergic
Neurons
The brain, as an energy expensive organ, consumes 20% of
the oxygen and glucose in the body (Zlokovic, 2011). Insulin
interacts with the blood brain barrier (BBB) to initiate signaling
pathways within the brain (Kastin and Akerstrom, 2001; Kondo
et al., 2004; Ueki et al., 2004; Banks et al., 2012). Appropriate
insulin levels are necessary to maintain sufficient glucose
transport to the brain (Reagan et al., 2001; Bingham et al., 2002;
McNay et al., 2010). Insulin action in the brain has been reported
to modulate neuronal survival, synaptic function, cognitive
function and neuronal circuit formation (Cholerton et al., 2011;
Banks et al., 2012). The hormone inhibits neuronal damage
resulting from glucose–oxygen deprivation (Sun et al., 2010),
excitotoxicity (Kim and Han, 2005) and oxidative stress (Ribeiro
et al., 2014). Insulin receptors have been found in midbrain
dopaminergic neurons (Figlewicz et al., 2003). It increases
dopaminergic transporter activity and enhances the clearance
of dopamine from the synapse (Davis et al., 2011). Insulin
action influences the function of the dopamine transporter,
which is a key regulator of dopamine neurotransmission (Speed
et al., 2011) and is important for cognitive ability (Figlewicz
and Benoit, 2009; Figlewicz and Sipols, 2010). In addition,
insulin signaling in dopaminergic neurons plays a crucial
role in energy balance and the reward system (Khanh et al.,
2014). Impaired insulin signaling aggravates brain dysfunction
related to dopamine homeostasis (Carvelli et al., 2002; Garcia
et al., 2005; Owens et al., 2005; Wei et al., 2007). Previous
researches demonstrated that brain insulin resistance controls
both the reward system and dopamine system (Luo et al.,
1999; Anthony et al., 2006). Moreover, insulin-like growth
factor (IGF-1) receptors within the substantia nigra (Dunn
and Castro, 1980), induce insulin signaling and stimulate the
activation of the phosphatidylinositol 3-kinase/AKT/glycogen
synthase kinase-3 beta and mitogen-activated protein kinase
pathways (Avila-Gomez et al., 2010) that modulate cell survival.
Several studies indicated that IGF-1 receptors could rescue
dopaminergic neurons from apoptosis (Cheng et al., 2011;
Zawada et al., 1996; Wang et al., 2010). Akt signaling related
to insulin signaling (Hage Hassan et al., 2015; Sadi et al., 2015;
Xu et al., 2015) is markedly associated with the regulation
of dopaminergic signaling (Beaulieu et al., 2007, 2009) and
dopaminergic homeostasis (Hanada et al., 2004; Garcia et al.,
2005; Williams et al., 2007). Notably, clinical research studies
reported that a human genetic variant of the Akt insulin signaling
pathway, found in patients, dysregulated the dopamine system
(Emamian et al., 2004; Ikeda et al., 2006). In in vivo studies,
genetic modification of Akt results in the dysregulation of
dopaminergic neuron homeostasis (Siuta et al., 2010). Another
study showed that a decrease in plasma insulin levels in rats,
results in impaired insulin action on dopaminergic neurons
(Patterson et al., 1998). Also, the ablation of insulin receptors
in dopaminergic neurons leads to intercellular damage to the
neurons (Könner et al., 2011), while insulin administration
to rats showed an increase in dopamine transporter protein
(Figlewicz et al., 1994). Moreover, insulin resistance in the
brain changes dopamine turnover and results in movement
disorders (Kleinridders et al., 2015). Insulin resistance caused
by a high-fat diet exacerbates dopaminergic degeneration in
mice (Bousquet et al., 2012). Clinical studies found increased
insulin resistance and decreased insulin concentrations in the
cerebrospinal fluid of patients with neurodegenerative disorders
(Bomfim et al., 2012; Talbot et al., 2012). Some surveys reported
an increased PD risk in patients with T2DM, accompanied
by insulin resistance (Hu et al., 2007; Sun et al., 2012). One
study found that Daf-2/Daf-16 insulin-like signaling pathway is
important in mechanisms connecting PD and diabetes such as
alpha-synuclein pathology of PD under high glucose conditions
(Fatima et al., 2014). Recent research, using in vitro and
in vivo models, demonstrated that appropriate insulin levels
could protect dopaminergic neuronal damage in the substantia
nigra during PD (Pang et al., 2016). Recently, drugs to treat
insulin resistance demonstrated protective effects in PD (Aviles-
Olmos et al., 2013a,b). Overall, the role of insulin signaling
on dopaminergic neurons in PD, in a background of T2DM-
related insulin resistance, should be investigated to understand
the underlying mechanisms.
Inflammation Caused by Hyperglycemia
and Dopaminergic Neurons
Several studies suggest that neuronal loss in PD is associated with
chronic neuroinflammation related to microglia and immune
cells in the brain (Barcia et al., 2003; Perry, 2012). Clinical studies
observed higher levels of pro-inflammatory factors such as
interleukin (IL)-1beta, IL-2, tumor necrosis factor (TNF)-alpha,
interferon (IFN)-gamma, and cluster of differentiation (CD)4+
and CD8+ T lymphocytes in PD brains (Dobbs et al., 1999;
Hisanaga et al., 2001; Reale et al., 2009). Microglial activation
in the substantia nigra (Lawson et al., 1990) was commonly
observed in PD patients (Doorn et al., 2014a), and in PD
animal models (Doorn et al., 2014b; Pisanu et al., 2014; Stott
and Barker, 2014). In oxidative stress caused by PD, microglia
promote an inflammatory state contributing to dopaminergic
neuronal degeneration (McGeer and McGeer, 2008; Frank-
Cannon et al., 2009; Burbulla et al., 2010). According to these
evidences, the activation of M2 type microglia which secrets
anti-inflammatory cytokines such as transforming growth factor
(TGF)-beta and IL-10 improves the pathology of PD. The
production of pro-inflammatory cytokines by inflammation
leads to the apoptosis of dopaminergic neuron. Impaired glucose
tolerance was observed in 80% of PD cases (Sandyk, 1993; Hu
et al., 2007). The high glucose condition in T2DM triggers
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oxidative stress and dopaminergic neuronal death (Giaccari
et al., 2009; Zhang et al., 2011; Renaud et al., 2014; Yoon and
Oh, 2015). Dopaminergic neurons in the brain deteriorate due
to increased production of reactive oxygen species (ROS) under
high glucose stress (Pearce et al., 1997; Brownlee, 2001; Cui
et al., 2012). These researches indicated that insulin level and
glucose dysregulation could influence dopaminergic neuron’s
degeneration. Clinical research found that dopaminergic
neurons were damaged through apoptosis signaling pathways,
such as p53 (Tatton, 2000; Hartmann and Hirsch, 2001; Nair,
2006), in PD patients, and an increase in activated microglia
was observed in the basal ganglia of PD patients (Ouchi et al.,
2005). One study found that long term incubation under
high glucose concentrations increased depolarization-induced
dopamine release (Koshimura et al., 2003). In addition, studies
also found a correlation between blood glucose levels and
cerebrospinal fluid concentrations of dopamine metabolites
(Umhau et al., 2003). Detrimental inflammatory conditions,
resulting from high glucose concentrations, have been reported
to induce degeneration and cell death of dopaminergic neurons
in PD animal models (Hu et al., 2007; Cai, 2009; Morris
et al., 2010; Machado et al., 2011; Yoon and Oh, 2015). In
summary, given that metabolic inflammation exacerbates
dopaminergic neuronal damage in response to T2DM (Wang
et al., 2014), the inflammatory environment caused by T2DM




Improper functioning of dopaminergic neurons in obesity is
an important issue (Stice et al., 2008). Reduced dopaminergic
receptor 2 expression in obesity, has been reported (Stice et al.,
2008, 2010). Another study found low expression levels of
dopaminergic receptor 2 in obese subjects compared to non-
obese controls (Wang et al., 2011). Dopamine D2 receptor in
the striatum was markedly lower in obese rats compared to
lean control rats (Hamdi et al., 1992). Moreover, one study
showed that dopamine transporter levels negatively correlated
with body mass index (BMI), suggesting that the dopamine
system regulates BMI (Chen et al., 2008). Recent studies indicated
that the improvement of dopamine function could be key to the
treatment of obese subjects (Avena et al., 2013a,b; Blum et al.,
2014; Curtis and Davis, 2014). The increase in dopaminergic
neuron receptors D1 and D2 reduces body fat, serum levels
of free fatty acid, glucose and insulin (Cincotta et al., 1997;
Conti et al., 2001). Freeman et al. (2001) investigated the
effect of glucose in dopamine neuronal activity and found
that a change in activity is influenced by caloric intake. One
study demonstrated that the dopamine system is sensitive
to alterations in energy metabolism (van der Plasse et al.,
2015). Dopaminergic neuron D2 receptor levels are inversely
associated with the BMI of obese subjects (Volkow et al., 2009;
Michaelides et al., 2012). According to some findings, obesity
FIGURE 1 | The schematic image regarding dopaminergic neuron’s degeneration caused by metabolic changes. This image shows that degeneration
of dopaminergic neuron was accelerated by aging-induced metabolic changes including high glucose, insulin action’s impairment, oxidative stress, and adipokines.
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associated genes control the activity of midbrain dopaminergic
circuitry (Hess et al., 2013). Dopaminergic neurons in the
midbrain are reported to play a crucial role in controlling
food seeking behavior (Salamone et al., 1997; Roitman et al.,
2004; van Zessen et al., 2012), by affecting the metabolic state
and some hormones (van Zessen et al., 2012). An in vivo
study using leptin-null mice (leptin is a key molecule, which
links metabolic information to reward signaling) showed that
feeding behavior is influenced by dopamine levels (Szczypka
et al., 2000). Recent research found a loss of dopaminergic
neurons due to metabolic dysregulation in an animal model
of obesity, under a chronic high fat diet (Khang et al.,
2015). Therefore, further studies on dopaminergic neuronal




CVD is generally accompanied by hypertension and
atherosclerosis due to the accumulation of atheromatous
plaques in coronary arteries, and is one of the main causes of
death worldwide (Braunwald, 1997). Some studies show that
cardiac failure is involved during the onset and prevalence of PD
(Zesiewicz et al., 2004; Ziemssen and Reichmann, 2007, 2010).
Based on clinical research, approximately 35% of PD patients
show cardiac denervations (Goldstein, 2006; Goldstein et al.,
2012; Martorell-Riera et al., 2014). Recent results support the
relationship betweenmitofusin 2, as a functional element in heart
mitophagy, and PTEN-induced putative kinase 1 (PINK1), as a
PD-related factor (Chen and Dorn, 2013). Cardiac sympathetic
denervation in PD is central to understanding the relationship
between CVD and dopaminergic neurons (Goldstein et al.,
2007). Dopamine plays a beneficial role in hypertension
patients (Lyzogub et al., 2014). Low dose dopamine activates
dopaminergic receptors, and ameliorates vasodilatation of the
coronary and cerebral vessels (Liang et al., 2008; Chen et al.,
2013). Cardiac sympathetic denervation is significantly related
to the loss of nigrostriatal dopaminergic neurons (Goldstein
et al., 2008, 2011, 2012). PD is associated with decreased
myocardial innervations and increased cardiac sympathetic
denervation (Orimo et al., 2002; Amino et al., 2005). Several
studies have reported the presence of the renin angiotensin
system (RAS) in basal ganglia, and high concentrations of
angiotensin converting enzyme have been found in the striatum
and substantia nigra of mammals (Chai et al., 1987; Allen
et al., 1992). An interaction between dopaminergic neurons and
angiotensin II receptors were demonstrated by several studies
on the regulation of cardiovascular function (Zeng et al., 2006;
Khan et al., 2008; Gildea, 2009). Recent findings show abnormal
interactions between dopaminergic neurons and angiotensin
II, affecting both neurodegenerative diseases and hypertension
(Gildea, 2009; Li et al., 2008). Chronic inhibition of RAS leads
to increased dopaminergic neuronal function (Jenkins et al.,
1997, 1999; Reardon et al., 2000; Villar-Cheda et al., 2010). RAS
hyperactivity is related to dopaminergic neuron degeneration in
PD, and involves oxidative stress and neuroinflammation (Villar-
Cheda et al., 2010). Collectively, understanding the mechanisms
connecting dopaminergic neuron degeneration and CVD, is a
fundamental issue to improve PD pathologies, as dopaminergic
neurons are involved in heart function by modulating the RAS
system and controlling cardiac inflammation.
CONCLUSION
Metabolic changes due to aging could affect multiple
neuropathological mechanisms, and may also contribute
to the progression and onset of PD (Figure 1). Insulin
resistance and the hyperglycemia condition caused by
T2DM lead to damage of dopaminergic neurons via several
signaling pathways. In addition, inflammation, adipokine
dysfunction and inappropriate energy metabolism by obesity,
trigger the loss and degeneration of dopaminergic neurons.
Heart failure related to RAS hyperactivity and cardiac
inflammation cause the degeneration of dopaminergic
neurons. Taken together, metabolic alterations could affect
dopaminergic neuronal loss and degeneration, leading to PD
neuropathology including motor disturbance and cognitive
decline. Hence, we suggest that manipulating dopaminergic
neuron degeneration by targeting metabolic pathways
propose therapeutic approaches to ameliorate metabolic
effects in PD.
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